Zhou, He
Nguyen, Hung http://orcid.org/0000-0003-1982-6825
Enriquez, Ana
Morsy, Louie
Curtis, Michael
Piser, Timothy
Kenney, Christopher
Stephen, Christopher D.
Gupta, Anoopum S.
Schmahmann, Jeremy D.
Vaziri, Ashkan
Funding for this research was provided by:
Cadent Therapeutics
Article History
Received: 20 May 2021
Accepted: 5 October 2021
First Online: 19 October 2021
Declarations
:
: This study was approved by the Partners HealthCare System Institutional Review Board and written informed consent was obtained from all participants.
: Informed written consent was obtained for all participants to participate in the study.
: Informed written consent was obtained for all participants that results from the study will be used for publication; however, their data will be anonymized.
: This study was sponsored by Cadent Therapeutics in collaboration with BioSensics and the Ataxia Center at Massachusetts General Hospital. The sensors used in the study were developed and commercialized by BioSensics. H. Zhou was a Senior Research Scientist at BioSensics. H. Nguyen is currently a Principal Research Scientist at BioSensics. A. Enrique is currently a Senior Clinical Operations Manager at BioSensics. L. Morsy is currently a Senior Clinical Operations Manager at BioSensics. M. Curtis was the President and Head of R&D at Cadent Therapeutics. T. Piser is currently the Chief Scientific Officer at Cadent Therapeutics. C. Kenney is currently the Chief Medical Officer at Cadent Therapeutics. C. Stephen has provided scientific advisory for Xenon Pharmaceuticals and SwanBio Pharma and received research funding from Sanofi-Genzyme for a study of video oculography in late-onset GM2 gangliosidosis. He has received financial support from Sanofi-Genzyme, Biogen, and Biohaven for the conduct of clinical trials. A.Gupta has received research funding from Biogen and consults for Biogen, Triplet Therapeutics, and Remix Therapeutics. J. Schmahmann is site Principal Investigator for Biohaven clinical trials NCT03701399, NCT02960893, and NCT03952806. He consults for Biogen, Bayer, and Cadent Therapeutics, and is the author of the BARS and BARS2 which are copyrighted by the General Hospital Corporation. A.Vaziri is the Founder and Chief Executive Officer of BioSensics.